| Autor: |
Paramo Ja, Gonzalez-Porras, Pardo A, Zamorano Jl, Fernandez E, Lopez-Fernandez T, de Haro J, Alvarez-Larran A, Steegmann Jl, Hernandez-Boluda Jc, Perez R, Roa-Chamorro R, Garcia-Gutierrez |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Annals of Hematology & Oncology. 8 |
| ISSN: |
2375-7965 |
| Popis: |
Progress in the treatment of Chronic Myeloid Leukaemia (CML) has significantly improved the survival rates and prognosis of these patients. As a result, there is a growing awareness of the adverse effects that the treatments used can have on the Cardiovascular (CV) system. A high percentage of patients develop sequential resistance to CML treatments and, in these cases, ponatinib represents a good therapeutic option that has been associated with cardiovascular events. This required the development of recommendations for its management. A Delphi analysis conducted by a multidisciplinary panel of experts developed and agreed on clinical practice recommendations to optimize cardiovascular risk control in CML patients requiring ponatinib treatment. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
